Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
CAR immune cells: design principles, resistance and the next generation
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
SM Albelda - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
Challenges and new technologies in adoptive cell therapy
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
X Zhang, H Zhang, H Lan, J Wu, Y **ao - Frontiers in immunology, 2023 - frontiersin.org
Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been
substantially improved with the emergence of novel therapeutic agents, such as proteasome …
substantially improved with the emergence of novel therapeutic agents, such as proteasome …
Cooperative CAR targeting to selectively eliminate AML and minimize escape
Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …
Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating
The success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …
Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development
Chimeric antigen receptor T cells (CAR-T) therapy has shown great potential in tumor
treatment. However, many factors impair the efficacy of CAR-T therapy, such as antigenic …
treatment. However, many factors impair the efficacy of CAR-T therapy, such as antigenic …
B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis
B-cell maturation antigen (BCMA), expressed in plasmablasts and plasma cells, could serve
as a promising therapeutic target for autoimmune diseases. We reported here chimeric …
as a promising therapeutic target for autoimmune diseases. We reported here chimeric …
Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies
Chimeric antigen receptor T cells have dramatically improved the treatment of hematologic
malignancies. T cell antigen receptor (TCR)-based cell therapies are yet to achieve …
malignancies. T cell antigen receptor (TCR)-based cell therapies are yet to achieve …
Treatment strategies for clear cell renal cell carcinoma: Past, present and future
J Yang, K Wang, Z Yang - Frontiers in oncology, 2023 - frontiersin.org
Clear cell renal cell carcinoma (ccRCC) is the most prevalent histological subtype of kidney
cancer, which is prone to metastasis, recurrence, and resistance to radiotherapy and …
cancer, which is prone to metastasis, recurrence, and resistance to radiotherapy and …